GRI Bio, Inc. Common Stock
Symbol: GRI (NASDAQ)
Company Description:
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
- Today's Open: $1.58
- Today's High: $1.625
- Today's Low: $1.52
- Today's Volume: 114.91K
- Yesterday Close: $1.57
- Yesterday High: $1.65
- Yesterday Low: $1.4683
- Yesterday Volume: 184.27K
- Last Min Volume: 167
- Last Min High: $1.605
- Last Min Low: $1.605
- Last Min VWAP: $1.605
- Name: GRI Bio, Inc. Common Stock
- Website: https://www.gribio.com
- Listed Date: 2023-04-24
- Location: LA JOLLA, CA
- Market Status: Active
- CIK Number: 0001824293
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $3.92M
- Round Lot: 100
- Outstanding Shares: 2.52M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-20 | 8-K | View |
| 2025-08-15 | 424B3 | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 10-Q | View |
| 2025-08-13 | S-8 | View |
| 2025-08-13 | 8-K | View |
| 2025-07-31 | 8-K | View |
| 2025-07-11 | ARS | View |
| 2025-07-11 | DEF 14A | View |
| 2025-06-26 | 8-K | View |